Relapsed Chronic Lymphocytic Leukemia
11
2
5
4
Key Insights
Highlights
Success Rate
80% trial completion
Clinical Risk Assessment
Based on trial outcomes
Moderate Risk
Score: 37/100
9.1%
1 terminated out of 11 trials
80.0%
-6.5% vs benchmark
0%
0 trials in Phase 3/4
75%
3 of 4 completed with results
Key Signals
Data Visualizations
Phase Distribution
Trial Status
Trial Success Rate
Benchmark: 86.5%
Based on 4 completed trials
Clinical Trials (11)
A Study of BGB-21447, a Bcl-2 Inhibitor, in Mature B-Cell Malignancies
Study of BGB-11417 in Participants With Relapsed or Refractory Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma
Acalabrutinib, Umbralisib, and Ublituximab (AU2) In Relapsed and Untreated CLL
Reduced Intensity Flu/Mel/TBI Conditioning for HAPLO HCT Patients With Hematologic Malignancies
A Pilot Study of Metformin Therapy in Patients With Relapsed Chronic Lymphocytic Leukemia (CLL) and Untreated CLL
UCB Transplant for Hematological Diseases Using a Non Myeloablative Prep
Allo HSCT Using RIC and PTCy for Hematological Diseases
Study of a Triple Combination Therapy, DTRM-555, in Patients With R/R CLL or R/R Non-Hodgkin's Lymphomas
Venetoclax Resistance Landscape in Chronic Lymphocytic Leukemia
Rituximab, Idelalisib, and Venetoclax in Relapsed/Refractory CLL/SLL
Intra-Osseous Co-Transplant of UCB and hMSC